Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Anavex Life Sciences to post earnings of ($0.16) per share for the quarter.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Anavex Life Sciences Stock Performance
Shares of Anavex Life Sciences stock opened at $9.50 on Thursday. Anavex Life Sciences has a 52-week low of $3.51 and a 52-week high of $14.44. The company has a fifty day moving average of $8.85 and a 200-day moving average of $8.83. The stock has a market capitalization of $808.11 million, a price-to-earnings ratio of -17.27 and a beta of 0.80.
Wall Street Analysts Forecast Growth
AVXL has been the topic of several analyst reports. D. Boral Capital reiterated a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright restated a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.
View Our Latest Stock Report on Anavex Life Sciences
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
